US EditionVagus Nerve Device OK'd for Rheumatoid Arthritis
UNITED STATES, JUL 31 – The Setpoint System reduces inflammation by stimulating the vagus nerve, with 35.2% of treated patients achieving significant symptom improvement in clinical trials.
- The US Food and Drug Administration approved the SetPoint System, the first vagus nerve stimulation device for rheumatoid arthritis patients who haven't responded to or can't tolerate biologic or targeted synthetic DMARDs.
- Nearly 75% of rheumatoid arthritis patients express dissatisfaction with current therapies and have discontinued them due to adverse side effects, while treatment involves strong anti-inflammatory medications increasing infection and cancer risks.
- In clinical trials, 242 participants with RA showed about 35% experienced symptom reduction versus 24% in the placebo group, with less than 2% facing serious adverse events.
- SetPoint plans to start commercialization in certain US cities this year, with a broader US expansion expected in early 2026.
- This approval marks the first time a device like this has been authorized for an autoimmune disorder, opening possibilities for treating inflammation-related conditions such as heart failure, diabetes, and neurodegenerative disorders.
12 Articles
12 Articles
The Food and Drug Administration (FDA) approved on Wednesday a medical device that offers new hope to patients disabled by rheumatoid arthritis, a chronic condition that affects 1.5 million Americans and is often resistant to treatment. The condition is usually controlled by medications. The device represents a radical deviation from standard care, taking advantage of the power of the brain and nervous system to placate uncontrolled inflammation…
Vagus Nerve Device OK'd for Rheumatoid Arthritis
(MedPage Today) -- SetPoint Medical's vagus nerve stimulator implant won FDA approval for treating rheumatoid arthritis (RA), the company announced Thursday. It's the first electrical therapy to win the agency's OK for the condition. Its approved...
FDA approves vagus nerve stimulator for rheumatoid arthritis
The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid arthritis.The device is an implantable, integrated neurostimulator about the size of a vitamin tablet that stimulates the vagus nerve for 60 seconds once daily with the goal of activating natural anti-inflammatory capabilities within the body. The device has also demonstrated
SetPoint is an innovative implant that stimulates the vagus nerve to block inflammation and paves the way for a new era in bioelectronic medicine
FDA approves SetPoint’s neuroimmune modulation device for RA treatment
The FDA has approved SetPoint Medical’s neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis.The post FDA approves SetPoint’s neuroimmune modulation device for RA treatment appeared first on Medical Device Network.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
